Ponatinib for chronic myeloid leukaemia: future perspectives
Mené sur 307 patients atteints d'une leucémie myéloïde chronique récemment diagnostiquée, cet essai international randomisé de phase III compare l'efficacité, du point de vue de la réponse moléculaire majeure à 12 mois, et la toxicité du ponatinib par rapport à l'imatinib
Ponatinib is a third-generation, multi-kinase inhibitor that has been shown to be more potent in vitro than any other tyrosine kinase inhibitor against BCR-ABL wild-type and mutated clones. Ponatinib was shown to be extremely effective in treatment-resistant or intolerant patients in phase 1 and phase 2 studies, irrespective of mutational status determined at baseline. Therefore, ponatinib was approved for use in patients with refractory Philadelphia chromosome-positive chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia, including patients with the BCR-ABL T315I mutation.
The Lancet Oncology , commentaire, 2015